Goldman Sachs Group Inc. trimmed its position in shares of Azenta, Inc. (NASDAQ:AZTA - Free Report) by 42.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 101,702 shares of the company's stock after selling 75,485 shares during the quarter. Goldman Sachs Group Inc. owned about 0.22% of Azenta worth $3,523,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its holdings in shares of Azenta by 788.1% during the 1st quarter. Farther Finance Advisors LLC now owns 968 shares of the company's stock valued at $33,000 after acquiring an additional 859 shares during the last quarter. State of Wyoming boosted its holdings in shares of Azenta by 77.1% during the 1st quarter. State of Wyoming now owns 2,343 shares of the company's stock valued at $81,000 after acquiring an additional 1,020 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Azenta by 13,184.2% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,524 shares of the company's stock valued at $87,000 after acquiring an additional 2,505 shares during the last quarter. Quarry LP boosted its holdings in shares of Azenta by 41.5% during the 1st quarter. Quarry LP now owns 3,120 shares of the company's stock valued at $108,000 after acquiring an additional 915 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Azenta by 8.9% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,842 shares of the company's stock valued at $168,000 after acquiring an additional 396 shares during the last quarter. 99.08% of the stock is owned by hedge funds and other institutional investors.
Azenta Price Performance
Azenta stock traded up $0.03 during trading hours on Friday, reaching $31.09. The stock had a trading volume of 2,052,486 shares, compared to its average volume of 488,771. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -12.85 and a beta of 1.65. The business's 50 day moving average price is $30.90 and its 200-day moving average price is $30.59. Azenta, Inc. has a 52 week low of $23.91 and a 52 week high of $55.63.
Azenta (NASDAQ:AZTA - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.19 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.06. The business had revenue of $143.94 million during the quarter, compared to the consensus estimate of $149.64 million. Azenta had a negative net margin of 18.45% and a positive return on equity of 1.35%. The firm's revenue was up .0% on a year-over-year basis. During the same period in the previous year, the company posted $0.14 earnings per share. On average, sell-side analysts forecast that Azenta, Inc. will post 0.53 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the stock. Raymond James Financial upgraded shares of Azenta from a "market perform" rating to an "outperform" rating and set a $35.00 price objective on the stock in a research note on Wednesday, August 6th. Evercore ISI set a $33.00 price objective on shares of Azenta and gave the stock an "in-line" rating in a research note on Tuesday, August 5th. Finally, Stephens assumed coverage on shares of Azenta in a research note on Tuesday, July 22nd. They issued an "equal weight" rating and a $35.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Azenta has an average rating of "Hold" and an average price target of $35.75.
Check Out Our Latest Analysis on Azenta
About Azenta
(
Free Report)
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Read More

Before you consider Azenta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.
While Azenta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.